ClinicalTrials.gg
RecruitingNCT07306468Updated Dec 29, 2025

Effects of Schizophrenia and Bipolar Disorder on Exercise Capacity, Pulmonary Function, and Quality of Life

An observational study in Schizophenia Disorder and Bipolar Disorder (BD), sponsored by Çankırı Karatekin University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Çankırı Karatekin University · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 45 studies in Bipolar Disorder with a site in Turkey — 10 open to participants now, 11 under way, none of them phase 3. Bipolar Disorder · Turkey.

Planned enrollment
5th of 19
150 · median 72
Started
2025
with 10 others
Observational
19 of 45
6 open now
Primary completion
2026-11
later than 3 of 10 live
Registered
29th of 45
by date

Among the 45 studies in Bipolar Disorder with a site in Turkey, this one is the 5th largest by planned enrollment of the 19 observational ones that give a count, is one of 11 that started in 2025, is one of 19 observational ones, reaches primary completion later than 3 of the 10 other live ones, and was the 29th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

10 of the 45 studies in Bipolar Disorder with a site in Turkey are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Bipolar Disorder with a site in Turkey, or all of them as a file.
02

Study summary

This observational study aims to evaluate exercise capacity, pulmonary function, respiratory muscle strength, and quality of life in individuals diagnosed with schizophrenia and bipolar disorder. These psychiatric conditions are associated with sedentary lifestyles, metabolic side effects of psychotropic medications, and increased comorbidity risks, all of which may negatively impact physical fitness and respiratory health. By assessing cardiorespiratory endurance, pulmonary parameters (FVC, FEV₁), and respiratory muscle strength in this population, the study seeks to identify physiological limitations and contribute to the development of more effective rehabilitation strategies. The findings may support multidisciplinary approaches to improving physical health and overall quality of life in individuals with severe mental illness.

Read the detailed description

Schizophrenia is a mental disorder observed in approximately 4 out of every 1,000 individuals in the general population, with a morbidity rate of 0.72%. According to the Global Burden of Disease Study (2010), around 20,000 deaths occur annually due to schizophrenia-related causes. Bipolar disorder is recognized as a chronic and severe mental illness. Based on data from the World Health Organization's global burden of disease reports, bipolar disorder ranks among the top 20 diseases contributing to disability worldwide and holds the 6th position among mental disorders.

Schizophrenia and bipolar disorder are serious and chronic psychiatric conditions affecting millions of individuals globally. The prevalence of schizophrenia is approximately 1%, while bipolar disorder has a lifetime prevalence of 2-3%. These disorders not only involve neuropsychiatric symptoms but also significantly impact physical health. In individuals with these conditions, sedentary lifestyle habits, metabolic side effects of antipsychotic and mood-stabilizing medications, and increased comorbidity risks are associated with notable reductions in exercise capacity.

Moreover, physical inactivity and heightened inflammatory processes may adversely affect respiratory muscle strength and pulmonary function. Studies have shown that patients with schizophrenia exhibit significantly lower maximal oxygen consumption (VO₂max) and anaerobic threshold levels compared to healthy individuals. In bipolar disorder, depressive episodes are marked by reduced exercise capacity, while manic episodes often involve irregular and risky physical activities.

Additionally, both disorders are associated with significantly lower pulmonary function parameters (FVC, FEV₁) compared to the healthy population. Respiratory muscle strength, a relatively underexplored area, is gaining importance. In schizophrenia cases dominated by negative symptoms, reduced inspiratory muscle strength combined with insufficient physical activity can severely limit patients' quality of life and independence. Similarly, in bipolar disorder, impairments in pulmonary capacity and respiratory muscle strength negatively affect quality of life.

Quality of life in these individuals is closely linked not only to mental health but also to physical capacity and pulmonary function. Enhancing respiratory muscle strength and aerobic capacity may positively influence overall quality of life, social participation, and functional status. However, the existing literature remains limited and fragmented. There is a noticeable lack of studies that simultaneously evaluate exercise capacity, pulmonary function, and respiratory muscle strength in individuals with psychiatric disorders.

This study aims to contribute to the literature from a multidisciplinary perspective by jointly examining exercise capacity, pulmonary function, respiratory muscle strength, and quality of life in individuals diagnosed with schizophrenia and bipolar disorder. These individuals often exhibit unhealthy lifestyle habits and a tendency toward sedentary behavior, which are considered risk factors that may adversely affect physical fitness. Components of physical fitness include cardiorespiratory endurance and muscular endurance. In light of this information, a review of the literature reveals that data on pulmonary function, respiratory muscle strength, and endurance in individuals with schizophrenia and bipolar disorder are still limited. The findings obtained from this study may guide the development of more effective rehabilitation and physical health support programs for these populations.

03

Conditions studied

  • Schizophenia Disorder
  • Bipolar Disorder (BD)

Keywords

  • schizophrenia
  • bipolar disorder
  • respiratory functions
  • quality of life
  • exercise capacity
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of individuals diagnosed with schizophrenia or bipolar disorder who are currently receiving standard medical treatment at the Community Mental Health Center of Çankırı State Hospital. Participants will be aged between 18 and 65 years, literate, and willing to participate in the study. No sampling method will be applied; all eligible individuals who meet the inclusion criteria and provide informed consent will be enrolled.

Based on a prior sample size analysis conducted using data collected under approved ethical clearance, the study aims to include a total of 150 participants-50 individuals in each diagnostic group (schizophrenia, bipolar disorder and healthy controls). This sample size is expected to provide sufficient statistical power to detect differences between groups in terms of exercise capacity, pulmonary function, respiratory muscle strength, and quality of life.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being volunteer for participation
  • Being 18 to 65 age

Exclusion criteria

Exclusion Criteria:

  • Having any respiratory, cardiac, neurologic or orthopedic disease which may affect respiratory functions or exercise capacity
  • Having any neuropsychiatric disease except schizophrenia or bipolar disorder
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Schizophrenia

    Patients diagnosed with schizophrenia

    Other: Pulmonary Function Test · Other: Respiratory Muscle Strength Evaluation · Other: Quality of Life Assessment · Other: Exercise Capacity Assessment

  • Bipolar Disorder

    Patients diagnosed with bipolar disorder

    Other: Pulmonary Function Test · Other: Respiratory Muscle Strength Evaluation · Other: Quality of Life Assessment · Other: Exercise Capacity Assessment

  • Healthy Control

    Participants who have any diagnosed diseases/disorders

    Other: Pulmonary Function Test · Other: Respiratory Muscle Strength Evaluation · Other: Quality of Life Assessment · Other: Exercise Capacity Assessment

Interventions

  • OtherPulmonary Function Test

    Participants' respiratory functions will assess with pulmonary function test according to ATS/ERS criteria

  • OtherRespiratory Muscle Strength Evaluation

    Participants' respiratory muscle strenght will assess with maximal inspiratory pressure and maximal expiratory pressure assessment according to ATS/ERS criteria

  • OtherQuality of Life Assessment

    Participants' quality of life will assess with WHOQOL-Bref questionnaire

  • OtherExercise Capacity Assessment

    Participants' exercise capacity will assess with 6 Minute Walk Test according to ATS/ERS criteria

06

What researchers measure

Primary outcomes

  1. Maximum Inspiratory Pressure (MIP) measurement

    MIP will be measured using a mouth pressure device on Day 1 of the intervention. The maximum inspiratory pressure (MIP) will be recorded in cmH₂O. Three assessments will be performed, and the highest value will be reported.

    Time frame: 1st day

  2. Maximum Expiratory Pressure (MEP) measured in cmH₂O

    MEP will be measured using a mouth pressure device on Day 1 of the intervention. The maximum expiratory pressure (MEP) will be recorded in cmH₂O. Three assessments will be performed, and the highest value will be reported.

    Time frame: 1st day

  3. Forced Expiratory Volume in 1 Second (FEV1) measured in liters

    FEV1 will be measured using spirometry on Day 1 of the intervention. The maximum expiratory volume in 1 second (FEV1) will be recorded in liters. Three assessments will be performed, and the highest value will be reported.

    Time frame: 1st day

  4. Forced Vital Capacity (FVC) measured in liters

    FVC will be measured using spirometry on Day 1 of the intervention. The forced vital capacity (FVC) will be recorded in liters. Three assessments will be performed, and the highest value will be reported.

    Time frame: 1st day

  5. FEV1/FVC ratio measured as a percentage

    FEV1/FVC ratio will be calculated using spirometry on Day 1 of the intervention. The ratio of FEV1 to FVC will be expressed as a percentage. Three assessments will be performed, and the highest value will be reported.

    Time frame: 1st day

  6. Peak Expiratory Flow (PEF) measurement

    PEF will be measured using spirometry on Day 1 of the intervention. The peak expiratory flow (PEF) will be recorded in liters per minute. Three assessments will be performed, and the highest value will be reported.

    Time frame: 1st day

Secondary outcomes

  1. 6-minute walk distance (6MWD) measured in meters

    The 6-minute walk test will be conducted according to standardized procedures in a straight corridor. Participants will be instructed to walk as far as possible in 6 minutes with standardized encouragement. The total distance walked will be recorded in meters. If a test is interrupted, the distance completed will be recorded. Two assessments will be performed on the same day, separated by a 30-minute rest interval. The 6-minute walk distance (6MWD) will be measured in meters, and the best (highest) distance will be reported.

    Time frame: 1st day

  2. WHOQOL-BREF total score measurement

    Health-related quality of life will be assessed using the Turkish version of WHOQOL-BREF questionnaire. Participants will complete the 26-item survey at the 1st day. The total score will be calculated according to standardized scoring procedures and reported in points. Higher scores indicate better quality of life.

    Time frame: 1st day

07

Study locations

1 of 1 sites recruiting
  • Çankırı Karatekin University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation
    Çankırı, Çankırı 18100, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.

Of 95 non-industry observational studies under Bipolar Disorder, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 119. This study's planned 12 months is below that.

Counting every sponsor, half of 105 studies reached it within 64 months; a quarter within 31 and three quarters within 119.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2025
First posted
Dec 29, 2025
StartActual
Nov 1, 2025
Primary completionEst.
Nov 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07306468
Lead sponsor
Çankırı Karatekin University
Responsible party
Furkan Özdemir (Lecturer, Çankırı Karatekin University) — Principal investigator
First posted
Dec 29, 2025
Start date
Nov 1, 2025
Primary completion
Nov 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Dec 29, 2025

Study contacts

Furkan Özdemir, PT, Ph.D.
Contact
furkanozdemir@karatekin.edu.tr
+905383264855

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion